samedan logo
home > pmps

Pharmaceutical Manufacturing and Packing Sourcer


Pharmaceutical Manufacturing and Packing Sourcer (PMPS) is a specialist journal designed to provide worldwide coverage of a range of topics relating to the pharmaceutical manufacturing and packaging sector.

Published quarterly, the journal functions as a platform of communication and information-sharing for executive and strategic decision makers within the industry, identifying new trends and marketing opportunities, as well as highlighting the latest innovations in this dynamic environment. PMPS is specifically designed to interest those in the pharma, biotech, nutritional, and medical device industries who are actively seeking to source services for improved efficiency in what is an increasingly competitive market 

For further information please contact:

Simon Caplan

Joseph O'Connor

We're also on Twitter! Follow us @PMPSmag  



Click here to view the digital version of PMPS



Click here to view the digital version of the Parenteral Technology Supplement


Featured in this issue
Feature topics
Strengthening Supply Chains with Graph Technology

Amy Hodler at Neo4j
Pharmaceutical, biotechnology, nutritional, and medical device industries have seen massive disruption. In many cases, supply chains have not been flexible enough to adapt to product shortages and increased demand for new substances and devices in the pandemic. Manufacturing and packaging operations that have been fine-tuned for efficiency over many years face requirements to pivot to new products almost overnight. Too often, understanding and changing complex data interdependencies in traditional structured query language (SQL) databases can delay the pace of change.
Pharmaceutical Labelling
Cracking the Code Mark in Pharma Labelling

Richard Pether at Rotech Machines

Pharmaceutical labelling has always been a key part of a product’s integrity. The label carries vital information on the drug type and strength, as well as traceability information printed onto the label at the point of packaging.

  COVID-19: The Effects on the Supply Chain
Smart Indicators for Time and Temperature in Healthcare

Nora Murphy at Timestrip

The coronavirus pandemic has brought into sharp relief a number of issues in the healthcare and medtech sectors, which were perhaps less well known previously. Among these is the monitoring of temperature and storage time on products that have a defined shelf life, or are most sensitive to their environment – everything from biological specimens and pharmaceutical products to the humble hospital curtain. Greater sensitivity to infection issues means that today’s healthcare professional needs to consider best practice in the deployment of disposable indicators for time and temperature.


Published quarterly in
February, May,
August, and November


Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement